सभी अध्ययन
भर्तीचरण2, चरण3हस्तक्षेपात्मक

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

This research is looking into a new gene therapy, RGX-202, for Duchenne muscular dystrophy (DMD). DMD is a condition where muscles weaken over time because a vital protein called dystrophin is missing. RGX-202 is designed to help muscle cells make a working version of this protein. The study will test how safe the treatment is, how well people tolerate it, and if it helps improve muscle strength. It's a multi-stage study, starting with a smaller group to check safety, then expanding to more boys. Participants will receive a single treatment given through a drip, and their health will be monitored for about two years afterwards.

एक नजर में

स्थिति
भर्ती
चरण
चरण2, चरण3
प्रायोजक
REGENXBIO Inc.
नामांकन लक्ष्य
65
प्रारंभ
04 Jan 2023
अनुमानित पूर्णता
01 Aug 2028

यह अध्ययन किस बारे में है?

Duchenne muscular dystrophy (DMD) is a genetic condition that causes muscles to become weak and waste away over time. This happens because the body can't make enough of a key protein called dystrophin, which is essential for healthy muscle function. Without it, muscle cells get damaged, leading to ongoing problems.

This study is investigating a new treatment called RGX-202. It's a type of gene therapy, which means it works by introducing new genetic information into the body. Specifically, RGX-202 aims to deliver a piece of genetic code to muscle cells. This code acts like a 'recipe' for a special, smaller version of the dystrophin protein that can still help muscles work.

The main goals of this research are to find out if RGX-202 is safe, if boys with DMD can tolerate the treatment well, and if it helps improve their muscle strength and function. The treatment is given once, through a drip into the vein. Boys in the study will also receive other medicines for a short time to prevent their body from reacting negatively to the gene therapy.

मुख्य निष्कर्ष

  • Tests a new gene therapy (RGX-202) for Duchenne muscular dystrophy.
  • Aims to help muscles make a working version of a missing protein.
  • Treatment is a single dose given into a vein.
  • Study monitors participants for around two years after treatment.
  • Participants will also take short-term medicines to help with the treatment.
  • Open to male participants aged 1 to <12 years old.

कौन पात्र हो सकता है?

This study is looking for boys who have Duchenne muscular dystrophy. They need to be male and at least 1 year old, but less than 12 years old. They should also meet a certain weight requirement (at least 10 kg).

To be considered, participants generally need to have specific changes in their DMD gene and may need to be able to walk a certain distance independently. They should also have been on a stable dose of steroid medication (a common treatment for DMD) for at least 12 weeks. Your doctor will check your child's general health, including their liver and kidney function, to make sure they are healthy enough to take part.

It's important that the child's parent or legal guardian understands the study and agrees to participate, and that they can bring their child to all scheduled appointments and follow the study instructions.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. Is my child male and between 1 and 12 years old?
  2. Does my child have a confirmed diagnosis of Duchenne muscular dystrophy?
  3. Can my child walk independently, or with minimal help (depending on the specific group)?
  4. Has my child been on a steady dose of steroid medication for at least 3 months?
  5. Are we able and willing to attend all study appointments over about two years?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you join this study, your child will receive the RGX-202 treatment once, through a drip into their vein. Before and during the treatment, your child will also take other medicines for a short time to help prevent any strong reactions to the gene therapy.

The study involves regular visits to the clinic over roughly two years to check your child's health, how they are tolerating the treatment, and if their muscles are improving. These visits will include various assessments, such as physical examinations, blood tests, and tests to measure muscle strength and function. After the main study period, there might be an option to join a separate long-term follow-up study to continue monitoring your child's health.

संभावित जोखिम और लाभ

Taking part in any clinical trial involves both potential benefits and risks. The potential benefit of this study is that RGX-202 could help improve muscle strength and overall health for boys with Duchenne muscular dystrophy. However, as this is a new treatment, there might be side effects or risks that are not yet fully known. The study team will carefully monitor your child for any problems, and you'll be given detailed information about known risks. Remember, participation is completely voluntary, and you have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

Locations (17)

  • आर्कांसस चिल्ड्रन हॉस्पिटल
    सत्यापित पोस्टकोड
    लिटिल रॉक, संयुक्त राज्य अमेरिका· भर्ती
  • Stanford School of Medicine /Division of Neuromuscular Medicine
    सत्यापित पोस्टकोड
    पैलो आल्टो, संयुक्त राज्य अमेरिका· भर्ती
  • चिल्ड्रन हॉस्पिटल कोलोराडो
    सत्यापित पोस्टकोड
    ऑरोरा, संयुक्त राज्य अमेरिका· भर्ती
  • University of Florida
    सत्यापित पोस्टकोड
    गेन्सविल, संयुक्त राज्य अमेरिका· भर्ती
  • Rare Disease Research
    सत्यापित पोस्टकोड
    अटलांटा, संयुक्त राज्य अमेरिका· भर्ती
  • एन एंड रॉबर्ट एच. लुरी चिल्ड्रन हॉस्पिटल ऑफ शिकागो
    सत्यापित पोस्टकोड
    शिकागो, संयुक्त राज्य अमेरिका· भर्ती
  • आयोवा विश्वविद्यालय
    सत्यापित पोस्टकोड
    आयोवा सिटी, संयुक्त राज्य अमेरिका· भर्ती
  • University of Massachusetts Chan Medical School
    सत्यापित पोस्टकोड
    Worcester, United States· भर्ती
  • Cincinnati Children's
    सत्यापित पोस्टकोड
    सिनसिनाटी, संयुक्त राज्य अमेरिका· भर्ती
  • ओरेगन स्वास्थ्य और विज्ञान विश्वविद्यालय
    सत्यापित पोस्टकोड
    पोर्टलैंड, संयुक्त राज्य अमेरिका· भर्ती
  • The University of Texas Southwestern Medical Center
    सत्यापित पोस्टकोड
    डलास, संयुक्त राज्य अमेरिका· भर्ती
  • Children's Hospital of the King's Daughters
    सत्यापित पोस्टकोड
    नॉरफ़ॉक, संयुक्त राज्य अमेरिका· भर्ती

सामान्य प्रश्न

ड्यूचेन मस्कुलर डिस्ट्रॉफी क्या है?

It's a genetic condition that causes muscles to become weak and waste away over time because the body can't make enough of a protein called dystrophin.

What is RGX-202?

It's a new gene therapy treatment designed to help muscle cells make a useful, smaller version of the missing dystrophin protein.

उपचार कैसे दिया जाता है?

It's given once as a single injection into a vein (like a drip).

मेरा बच्चा इस अध्ययन में कितने समय तक रहेगा?

Participants will be monitored for about two years after receiving the treatment, with regular check-ups.

Can girls join the study?

No, this specific study is only for male participants.

और अधिक जानने के लिए कैसे पता करें

Patient Advocacy

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With…यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.